A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS). This panel discussion adds to the conversation from our previous AJMC® Peer Exchange, in which we ...
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
Myelodysplastic syndromes (MDS) are blood cancers where bone marrow makes too few healthy blood cells. Many of the cells produced die early or do not function normally. Early myelodysplastic syndromes ...
ascopubs.org: Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes
Myelodysplastic syndromes are a heterogeneous group of neoplastic hematopoietic stem cell disorders. The common features of the disease include (1) clinical presentation with variant cytopenias and ...
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes
Myelodysplastic syndromes, also called myelodysplasia or MDS, is the name for a group of conditions that cause the number of normal blood cells to drop. In these syndromes, the bone marrow does not ...
Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas Myelodysplastic syndrome (MDS) classification currently relies mainly on its morphologic features and ...
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need ...
Nutrition may improve quality of life and outcomes in people with myelodysplastic syndromes (MDS). Myelodysplastic syndromes (MDS) are a type of blood cancer. Typically, blood stem cells mature into ...